• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人体血液透析过程中皮质醇代谢的研究。

Studies on cortisol metabolism during haemodialysis in man.

作者信息

Deck K A, Fischer B, Hillen H

出版信息

Eur J Clin Invest. 1979 Jun;9(3):203-7. doi: 10.1111/j.1365-2362.1979.tb00924.x.

DOI:10.1111/j.1365-2362.1979.tb00924.x
PMID:113221
Abstract

Plasma clearance rates and dialysance of labelled cortisol were measured in patients on chronic intermittent dialysis during and after dialysis. Plasma clearance rates during dialysis were 30--63% higher than after dialysis; dialysance was 0.3--0.7 1/h and accounted only for 20--35% of the increase of plasma clearance rates during dialysis. After bolus injection of labelled cortisol, disappearance curves were obtained in two normal subjects and two uraemic subjects on and off dialysis. Biological halftimes of the different segments of the disappearance curves and distribution volumes were calculated. The size of the inner compartment (V1) is greater in uraemia. The disappearance curves flatten after the end of dialysis, indicating an increase of biological halftime after dialysis. Plasma 17-OHCS-glucuronides dropped from 2.13 +/- 0.62 micromol/l (n = 20) at the beginning to 1.05 +/- 0.65 micromol/l at the end of dialysis and increased to 1.51 +/- 0.43 micromol/l (n = 12) within 3 h thereafter. During dialysis cortisol metabolites are removed from the blood. This may decrease inhibition of cortisol metabolism by the end products of cortisol metabolism which might explain the more rapid plasma clearance and the shortened cortisol half-life during haemodialysis.

摘要

在慢性间歇性透析患者透析期间及透析后,测量了标记皮质醇的血浆清除率和透析率。透析期间的血浆清除率比透析后高30% - 63%;透析率为0.3 - 0.7升/小时,仅占透析期间血浆清除率增加量的20% - 35%。在对两名正常受试者以及两名透析和未透析的尿毒症受试者静脉注射标记皮质醇后,获得了清除曲线。计算了清除曲线不同部分的生物半衰期和分布容积。尿毒症患者体内室(V1)的大小更大。透析结束后清除曲线变平缓,表明透析后生物半衰期延长。血浆17 - OHCS - 葡糖醛酸苷在透析开始时为2.13±0.62微摩尔/升(n = 20),在透析结束时降至1.05±0.65微摩尔/升,并在之后3小时内升至1.51±0.43微摩尔/升(n = 12)。透析期间皮质醇代谢产物从血液中被清除。这可能会减少皮质醇代谢终产物对皮质醇代谢的抑制作用,这或许可以解释血液透析期间血浆清除更快以及皮质醇半衰期缩短的现象。

相似文献

1
Studies on cortisol metabolism during haemodialysis in man.人体血液透析过程中皮质醇代谢的研究。
Eur J Clin Invest. 1979 Jun;9(3):203-7. doi: 10.1111/j.1365-2362.1979.tb00924.x.
2
[Diurnal rhythm of cortisol and aldosterone plasma levels in patients with chronic renal insufficiency].
Srp Arh Celok Lek. 1996 May-Jun;124(5-6):115-9.
3
Plasma clearance of cortisol as a function of plasma cortisol levels in normal and obese persons and in patients with uraemia or cirrhosis of the liver.正常人和肥胖者以及尿毒症或肝硬化患者中皮质醇的血浆清除率与血浆皮质醇水平的关系。
Acta Endocrinol (Copenh). 1979 May;91(1):122-33. doi: 10.1530/acta.0.0910122.
4
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.终末期肾病血液透析患者依度沙班的药代动力学、安全性和耐受性。
Thromb Haemost. 2015 Apr;113(4):719-27. doi: 10.1160/TH14-06-0547. Epub 2015 Jan 8.
5
Activation of L-arginine transport in undialysed chronic renal failure and continuous ambulatory peritoneal dialysis patients.未透析的慢性肾衰竭患者及持续性非卧床腹膜透析患者中L-精氨酸转运的激活
Clin Exp Pharmacol Physiol. 2006 Jan-Feb;33(1-2):114-8. doi: 10.1111/j.1440-1681.2006.04333.x.
6
Cortisol binding in uremic plasma. I. Absence of abnormal cortisol binding to cortisol binding to corticosteroid-binding globulin.尿毒症血浆中的皮质醇结合。I. 未发现皮质醇与皮质类固醇结合球蛋白的结合存在异常。
Nephron. 1984;37(3):160-5. doi: 10.1159/000183237.
7
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.在慢性尿毒症患者中使用直接凝血酶抑制剂美拉加群预防血液透析期间的血栓形成。
Nephrol Dial Transplant. 2005 Sep;20(9):1889-97. doi: 10.1093/ndt/gfh915. Epub 2005 May 31.
8
Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.奥硝唑在肾功能不全患者中的药代动力学;血液透析和腹膜透析的影响。
Br J Clin Pharmacol. 1985 Feb;19(2):211-7. doi: 10.1111/j.1365-2125.1985.tb02633.x.
9
Effect of haemodialysis on metoclopramide kinetics in patients with severe renal failure.血液透析对严重肾衰竭患者胃复安药代动力学的影响。
Br J Clin Pharmacol. 1988 Oct;26(4):474-7. doi: 10.1111/j.1365-2125.1988.tb03408.x.
10
Factor VIII complex in uraemia and effects of haemodialysis.尿毒症中的凝血因子 VIII 复合物及血液透析的影响
Br Med J (Clin Res Ed). 1981 May 23;282(6277):1653-6. doi: 10.1136/bmj.282.6277.1653.

引用本文的文献

1
Hair cortisol and changes in cortisol dynamics in chronic kidney disease.慢性肾脏病中的毛发皮质醇和皮质醇动态变化。
Front Endocrinol (Lausanne). 2024 Mar 25;15:1282564. doi: 10.3389/fendo.2024.1282564. eCollection 2024.
2
Performance of synacthen test in chronic hemodialysis patients.促肾上腺皮质激素兴奋试验在慢性血液透析患者中的表现。
BMC Nephrol. 2023 Nov 7;24(1):330. doi: 10.1186/s12882-023-03347-3.
3
Cortisol excess in chronic kidney disease - A review of changes and impact on mortality.慢性肾脏病中的皮质醇过多——变化及其对死亡率影响的综述。
Front Endocrinol (Lausanne). 2023 Jan 17;13:1075809. doi: 10.3389/fendo.2022.1075809. eCollection 2022.
4
Adrenal function testing in dialysis patients - a review of the literature.透析患者的肾上腺功能检测——文献综述。
BMC Nephrol. 2021 Nov 1;22(1):360. doi: 10.1186/s12882-021-02541-5.
5
Hypoglycaemic coma due to adrenal failure in a chronic haemodialysis patient.一名慢性血液透析患者因肾上腺功能衰竭导致低血糖昏迷。
NDT Plus. 2011 Feb;4(1):36-8. doi: 10.1093/ndtplus/sfq188. Epub 2010 Nov 12.